Our Heritage is In Hematology
American Society of Hematology Annual Meeting 2019
A Letter from Our CEO
10 years. That’s how long it’s been since Agios opened its labs with the promise to accelerate discovery in the field of cellular metabolism. Later that same year, Nature published the groundbreaking research from our scientists, which found that IDH mutations were driving the proliferation of a wide range of blood and solid tumor cancers. This discovery led to our first clinical trial in acute myeloid leukemia, and our next big scientific breakthrough led to the development of the first potential therapy for a rare hemolytic anemia called pyruvate kinase deficiency.
Our roots are in hematology, and at this year’s American Society of Hematology (ASH) Annual Meeting, we’re celebrating the great science that got us here, unveiling new findings that help us further understand the role that IDH mutations and PKR activation play in hematologic diseases, and learning from this tremendous community that shares our dedication to making a difference for patients.
We look forward to presenting new data across our pipeline in Orlando. Visit us at our booth and come learn more about our leadership in understanding IDH inhibition in cancer and PKR activation in hematolytic anemias. I also invite you to follow us on Twitter and LinkedIn and engage in the conversation using #HeritageinHeme.
Jackie Fouse, Ph.D.
Chief Executive Officer
For 10 years, we have pioneered the science behind IDH mutations in hematologic malignancies and PKR activation in rare hemolytic anemias.
Promise of IDH
is at our Core